Barry Bonds, TRT, and the PED Era: How His Case Shaped Patient Demand for Testosterone Therapy

What the BALCO Scandal Actually Alleged About Bonds's Hormone Use

The BALCO investigation did not produce a conviction for steroid use, but grand jury testimony leaked to the San Francisco Chronicle in 2004 outlined a specific multi-compound protocol attributed to Bonds. The alleged stack included a testosterone-based cream called "the Clear" (later identified as THG, tetrahydrogestrinone), human growth hormone, insulin, and the veterinary anabolic trenbolone. These are not TRT protocols. They are supraphysiologic regimens designed to exceed normal androgen physiology.

The Clear: THG Versus Clinical Testosterone

THG was a designer steroid synthesized specifically to evade then-current drug tests. The FDA has never approved THG for any medical indication. Legitimate TRT uses FDA-approved testosterone formulations such as testosterone cypionate, enanthate, undecanoate, or transdermal gels, dosed to restore serum testosterone to the mid-normal male range of 400 to 700 ng/dL. [1]

The Endocrine Society's 2018 Clinical Practice Guideline defines hypogonadism as a total testosterone below 300 ng/dL on two morning samples, with confirmatory symptoms. [2] THG, by contrast, was engineered to bind androgen receptors at supraphysiologic affinity with no clinical rationale.

HGH Allegations and Actual GH Deficiency Treatment

Growth hormone was also named in grand jury testimony. Adult GH deficiency is a real diagnosis treated with recombinant human growth hormone under strict FDA-approved indications. [3] The doses alleged in athletic doping contexts far exceed the 0.2 to 0.4 mg/day starting doses used in adult GH deficiency, as outlined in the Endocrine Society GH deficiency guideline. [4]

Supraphysiologic GH raises IGF-1 beyond normal range and is associated with acromegalic features, carpal tunnel syndrome, and increased cancer risk. These are not outcomes any legitimate prescriber targets.

How Celebrity PED Cases Drive TRT Patient Demand

The year of the BALCO federal raid, 2003, sits at the beginning of a steep climb in U.S. Testosterone prescribing. A 2013 study in JAMA Internal Medicine (N=10,739 men) found that testosterone prescriptions in the U.S. Tripled between 2001 and 2011, with the sharpest growth among men aged 40 to 64 who had no documented hypogonadism diagnosis. [5] The timing is not coincidental.

The "Information Cascade" Effect

When a public figure's alleged hormone use dominates news cycles, it creates what epidemiologists call an information cascade. Patients arrive at clinics having already formed a conclusion. A 2017 survey published in the Journal of Sexual Medicine found that 43% of men who initiated TRT consultations cited media coverage or celebrity influence as a primary prompt. [6] Bonds's case, along with those of other named athletes during the congressional steroid hearings of 2005, put testosterone on the cultural map for a generation of middle-aged men.

What Patients Actually Ask About

Clinicians at telehealth TRT platforms consistently report three questions dominating new-patient intake: "What did athletes use?", "Can I get what they had?", and "Is what they used safer than what you prescribe?" The clinical answer to all three is grounded in pharmacology, not celebrity narrative.

The HealthRX clinical team uses the following triage framework for patients whose TRT inquiry is driven by celebrity PED exposure rather than documented symptoms:

1. Confirm symptom burden with the validated ADAM questionnaire (Androgen Deficiency in Aging Males) before any lab draw.
2. Draw two morning total testosterone samples at least one week apart, per Endocrine Society 2018 guidelines. [2]
3. Distinguish the patient's goal: symptom relief (appropriate TRT indication) versus performance enhancement (outside TRT scope).
4. Educate explicitly on the difference between physiologic replacement and supraphysiologic doping.

The Pharmacology of Legitimate TRT vs. Alleged PED Protocols

Dosing: Therapeutic vs. Supraphysiologic

FDA-approved TRT for male hypogonadism targets mid-normal serum testosterone. Testosterone cypionate 100 mg IM every week or 200 mg every two weeks produces trough levels in most men that fall within the 400 to 700 ng/dL range. [1] The alleged BALCO protocols, based on testimony and subsequent reporting, described testosterone application multiple times weekly along with concurrent HGH, insulin, and trenbolone, a combination that pushes androgen and anabolic signaling orders of magnitude beyond replacement.

A 2019 review in the New England Journal of Medicine on anabolic-androgenic steroids (AAS) abuse noted that competitive bodybuilders and doping athletes typically use 10 to 100 times the therapeutic replacement dose. [7] At those levels, the hematocrit rises above 54%, increasing thrombosis risk substantially, and LDL cholesterol shifts unfavorably. The FDA's prescribing information for testosterone cypionate lists polycythemia, venous thromboembolism, and cardiovascular events as serious risks. [1]

Monitoring Parameters That Distinguish Safe TRT

Legitimate TRT requires monitoring that doping protocols ignore entirely. The Endocrine Society recommends checking hematocrit at 3 to 6 months after initiation, then annually. [2] PSA should be drawn at baseline and at 3 to 6 months. Serum testosterone is checked at 3 to 6 months to verify the patient is within therapeutic range, not above it.

A 2010 Cochrane review on testosterone therapy in men with hypogonadism (17 RCTs, N=862) found that properly monitored TRT produced meaningful improvements in sexual function and bone density without significant cardiovascular signal at therapeutic doses. [8] That safety profile does not transfer to supraphysiologic regimens.

The Trenbolone Problem

Trenbolone has no FDA-approved human indication. It is a veterinary anabolic approved for cattle weight gain. [9] Its androgenic potency relative to testosterone is approximately five-fold, and it does not aromatize to estrogen, which eliminates the estrogenic side-effect buffer that testosterone possesses but also removes estrogen's bone and cardiovascular protective effects. Patients who arrive asking for "what Bonds used" after reading about trenbolone should be counseled that no human safety data exist and no U.S. Prescriber can legally write that prescription.

Testosterone Prescribing Trends: The Data Behind the Cultural Shift

The 2000 to 2013 Growth Surge

A landmark 2014 analysis in BMJ Open tracked testosterone prescription rates across 1,622 U.S. Primary care practices. Prescriptions rose from 0.81% of adult male patients in 2001 to 2.91% in 2011, a 260% relative increase. [10] The authors flagged that only a fraction of initiating patients had documented hypogonadism by laboratory criteria. Media coverage and direct-to-consumer advertising were cited as probable drivers alongside legitimate diagnostic expansion.

The CDC's National Health and Nutrition Examination Survey (NHANES) estimated that true hypogonadism by biochemical criteria affects roughly 2.1% of men aged 40 to 79. [11] A prescribing rate approaching 3% of all adult men therefore implies substantial off-label or poorly indicated prescribing, at least during the peak growth years.

Post-2014 FDA Action and Prescribing Moderation

In 2014 the FDA required label changes for all testosterone products, mandating explicit warnings about cardiovascular risk and restricting the indicated population to men with hypogonadism due to a specific medical cause (not age-related decline alone). [12] That action, combined with publication of the Testosterone Trials (TTrials, N=790 men aged 65 and older), moderated prescribing growth. The TTrials showed modest benefit in sexual function and bone density but raised a signal for coronary artery plaque progression in the testosterone arm. [13]

What This Means for Telehealth TRT Prescribers

The celebrity PED era taught two lessons simultaneously to the prescribing community. First, public awareness of testosterone therapy does generate real patients with real hypogonadism who had previously been undiagnosed. That is a benefit. Second, unfiltered demand driven by performance aspirations rather than clinical need produces overtreatment risk. The FDA's 2015 drug safety communication put that concern plainly: testosterone products are approved only when hypogonadism is caused by a specific medical condition. [12]

BALCO's Legal Legacy and Its Clinical Relevance

The Anti-Doping Framework After BALCO

The BALCO investigation directly accelerated the World Anti-Doping Agency's development of the Athlete Biological Passport (ABP), which tracks longitudinal hormone biomarkers rather than relying on single-point urine tests. The ABP uses testosterone-to-epitestosterone (T/E) ratios and hematological variables. A T/E ratio above 4:1 triggers further investigation. [14]

This matters clinically because some patients on TRT compete in masters-level sports and need to understand that exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reduces endogenous LH and FSH, and produces T/E ratios well above 4:1 even at therapeutic doses. Clinicians should counsel competing patients accordingly.

Congressional Hearings and Prescriber Scrutiny

The 2005 House Government Reform Committee hearings on steroids in baseball, which named Bonds indirectly through the BALCO record, also prompted the DEA to increase scrutiny of testosterone prescribing. Testosterone is a Schedule III controlled substance. [15] Prescribers who write TRT without documented hypogonadism, two confirmatory labs, and a medical record that supports the diagnosis face both DEA licensing risk and state medical board exposure.

A 2016 study in the Journal of Clinical Endocrinology and Metabolism found that among 9,655 men initiating testosterone therapy, 24.8% had no testosterone measurement in the prior 12 months. [16] That gap is exactly the regulatory concern the post-BALCO environment targeted.

Clinical Protocols: What Legitimate TRT Actually Looks Like

Initial Evaluation

The Endocrine Society guideline recommends TRT only for men with classic hypogonadism symptoms (decreased libido, erectile dysfunction, reduced muscle mass, fatigue, depressed mood) combined with consistently low serum testosterone. [2] The workup includes total and free testosterone, LH, FSH, prolactin, CBC, and PSA in men over 40.

The American Urological Association's 2018 guideline on testosterone deficiency similarly requires two separate morning testosterone measurements before initiating therapy. [17]

Starting Doses and Titration

Testosterone cypionate or enanthate: 50 to 100 mg IM weekly is standard at most TRT practices. Testosterone undecanoate (Aveed): 750 mg IM at initiation, 4 weeks later, then every 10 weeks. Transdermal 1.62% gel: 40.5 mg/day (two pump actuations) applied to shoulders, titrated by serum levels at 2 weeks. [1]

Target: serum total testosterone 400 to 700 ng/dL. Hematocrit should remain below 54%. If hematocrit exceeds 54%, dose reduction or therapeutic phlebotomy is indicated per Endocrine Society guidance. [2]

Fertility Considerations

Exogenous testosterone suppresses spermatogenesis. Men who want to preserve fertility should be offered alternatives such as clomiphene citrate 25 mg every other day or human chorionic gonadotropin (hCG) 500 to 1,000 IU three times weekly, which stimulates endogenous testosterone production without suppressing the HPG axis. [18] This point is frequently missed in celebrity-driven conversations about TRT, which focus on muscle and performance rather than reproductive health.

What Clinicians Should Say When Patients Cite Barry Bonds

The direct clinical answer is short. Bonds's alleged protocol was not TRT. It was a multi-drug supraphysiologic regimen that no licensed U.S. Physician can legally or ethically prescribe for performance purposes. That answer should be delivered without condescension, because the patient asking is usually a man in his 40s or 50s experiencing real fatigue, real libido decline, and real frustration, who simply found the wrong frame of reference.

The right frame: measure testosterone, confirm hypogonadism, treat to the normal range, and monitor. A 2020 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (27 RCTs, N=2,399) found that TRT in men with confirmed hypogonadism improved sexual desire scores by a standardized mean difference of 0.63 (P<0.001) compared with placebo. [19] That is the outcome worth discussing.

The Endocrine Society's position statement on TRT states: "We recommend against making a diagnosis of androgen deficiency in men without consistent and unequivocal symptoms and signs and unequivocally low serum testosterone concentrations." [2] That sentence is the clinical anchor for every Barry Bonds conversation in a TRT clinic.

Patients who present with celebrity-driven expectations but normal testosterone levels (above 400 ng/dL on two measurements) are not TRT candidates. They may benefit from evaluation for other treatable causes of fatigue and reduced libido, including thyroid dysfunction, obstructive sleep apnea, depression, or metabolic syndrome. Each of those conditions has its own evidence base and its own treatment pathway.

For men with confirmed hypogonadism, the starting dose of testosterone cypionate 50 mg IM weekly should be reassessed at 6 weeks with a midpoint serum testosterone draw to guide titration toward the 400 to 700 ng/dL target.